Kalvista Pharmaceuticals, Inc. (KALV) — SEC Filings
Kalvista Pharmaceuticals, Inc. (KALV) — 50 SEC filings. Latest: 10-KT (Mar 25, 2026). Includes 22 8-K, 9 SC 13G/A, 6 SC 13G.
View Kalvista Pharmaceuticals, Inc. on SEC EDGAR
Overview
Kalvista Pharmaceuticals, Inc. (KALV) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-KT filed on Mar 25, 2026: KalVista Pharmaceuticals, Inc. filed a 10-KT transition report on March 25, 2026, for the period ending December 31, 2025. This filing indicates a change in their fiscal year end from April 30 to December 31, which is a significant operational and reporting adjustment. This matters to investors beca
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 3 bullish, 1 bearish, 42 neutral, 4 mixed. The dominant filing sentiment for Kalvista Pharmaceuticals, Inc. is neutral.
Filing Type Overview
Kalvista Pharmaceuticals, Inc. (KALV) has filed 1 10-KT, 22 8-K, 5 10-Q, 2 10-K, 9 SC 13G/A, 6 SC 13G, 4 SC 13D/A, 1 DEF 14A with the SEC between Jan 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of KALV's 35 recent filings, 2 were flagged as high-risk, 19 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $13.692M |
| Net Income | -$49.482M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $243.497M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Dr. Andrew Sinclair
- Ms. Sarah Kelly
- Albert Cha
- Daniel Estes
- Andrew Sinclair
- Sarah O'Connor
- Michael R. Bristow
- David E. Johnson
- Dr. Sarah Schlesinger
- Chen Yu
- Dr. Andrew Hinton
- Dr. Michael Stein
- James N. Topper
- Abigail P. Johnson
Industry Context
The biopharmaceutical industry, particularly in rare diseases like Hereditary Angioedema (HAE), is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. Companies often rely on breakthrough therapies to achieve market success. The HAE market is competitive, with established treatments and emerging therapies vying for patient and physician adoption.
Top Tags
corporate-governance (5) · pharmaceuticals (5) · Biotechnology (4) · financials (4) · Pharmaceuticals (3) · Hereditary Angioedema (3) · Net Loss (3) · filing (3) · sec-filing (3) · material-agreement (3)
Executive Compensation
From the most recent 10-K filing (Jul 10, 2025):
- Andrew Thompson — Chief Executive Officer: $1,100,000
- Calum Macarthur — Chief Financial Officer: $700,000
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Product revenue, net | $13.692M | First-time revenue for the three and nine months ended September 30, 2025 |
| Net loss (3 months) | $49.482M | Increased from $39.084 million in Q3 2024 |
| Net loss (9 months) | $158.914M | Increased from $122.529 million in the prior year period |
| Selling, general and administrative expenses (3 months) | $46.517M | Increased from $24.800 million in Q3 2024, reflecting commercialization efforts |
| Selling, general and administrative expenses (9 months) | $125.997M | Increased from $63.511 million in the prior year period, reflecting commercialization efforts |
| Cash and cash equivalents | $243.497M | As of September 30, 2025, up from $182.326 million at December 31, 2024 |
| Proceeds from convertible notes | $139.438M | Received during the nine months ended September 30, 2025 |
| Proceeds from royalty agreement | $21.259M | Received during the nine months ended September 30, 2025 |
| Accumulated deficit | $739.098M | As of September 30, 2025, indicating historical losses |
| Shares outstanding | 50,546,293 | As of November 3, 2025 |
| Product Revenue | $1.426M | First period generating product revenue, up from $0 in prior year. |
| Net Loss | ($60.096M) | Increased from ($40.443M) in the prior year, indicating widening losses. |
| Selling, General and Administrative Expenses | $44.683M | More than doubled from $17.601M, reflecting EKTERLY commercialization. |
| Research and Development Expenses | $15.162M | Decreased from $26.614M, indicating a shift in focus post-approval. |
| Accumulated Deficit | $713.3M | Increased from $653.170M, highlighting historical losses. |
Forward-Looking Statements
- {"claim":"KalVista Pharmaceuticals, Inc. may see increased institutional interest following this disclosure.","entity":"KalVista Pharmaceuticals, Inc.","targetDate":"Q2 2024","confidence":"medium"}
- {"claim":"KalVista Pharmaceuticals' stock price may experience downward pressure due to the reduced institutional ownership.","entity":"KalVista Pharmaceuticals, Inc.","targetDate":"Q2 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Kalvista Pharmaceuticals, Inc. (KALV)?
Kalvista Pharmaceuticals, Inc. has 50 recent SEC filings from Jan 2024 to Mar 2026, including 22 8-K, 9 SC 13G/A, 6 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of KALV filings?
Across 50 filings, the sentiment breakdown is: 3 bullish, 1 bearish, 42 neutral, 4 mixed. The dominant sentiment is neutral.
Where can I find Kalvista Pharmaceuticals, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Kalvista Pharmaceuticals, Inc. (KALV) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Kalvista Pharmaceuticals, Inc.?
Key financial highlights from Kalvista Pharmaceuticals, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for KALV?
The investment thesis for KALV includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Kalvista Pharmaceuticals, Inc.?
Key executives identified across Kalvista Pharmaceuticals, Inc.'s filings include Dr. Andrew Sinclair, Ms. Sarah Kelly, Albert Cha, Daniel Estes, Andrew Sinclair and 9 others.
What are the main risk factors for Kalvista Pharmaceuticals, Inc. stock?
Of KALV's 35 assessed filings, 2 were flagged high-risk, 19 medium-risk, and 14 low-risk.
What are recent predictions and forward guidance from Kalvista Pharmaceuticals, Inc.?
Recent forward-looking statements from Kalvista Pharmaceuticals, Inc. include guidance on {"claim":"KalVista Pharmaceuticals, Inc. may see increased institutional interest following this disclosure.","entity":" and 1 other predictions.